Journal Article10.1038/NATURE04478
Angiogenesis in life, disease and medicine
3.5K
TL;DR: Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments.
read more
Abstract: The growth of blood vessels (a process known as angiogenesis) is essential for organ growth and repair. An imbalance in this process contributes to numerous malignant, inflammatory, ischaemic, infectious and immune disorders. Recently, the first anti-angiogenic agents have been approved for the treatment of cancer and blindness. Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Alginate: properties and biomedical applications
Kuen Yong Lee,David J. Mooney +1 more
TL;DR: This review will provide a comprehensive overview of general properties of alginate and its hydrogels, their biomedical applications, and suggest new perspectives for future studies with these polymers.
6.9K
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet,Rakesh K. Jain +1 more
TL;DR: Preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.
Type 2 diabetes as an inflammatory disease.
TL;DR: Preliminary results from clinical trials with salicylates and interleukin-1 antagonists support the notion that inflammation participates in the pathogenesis of type 2 diabetes and have opened the door for immunomodulatory strategies for the treatment of T2D that simultaneously lower blood glucose levels and potentially reduce the severity and prevalence of the associated complications of this disease.
3.4K
Modes of resistance to anti-angiogenic therapy.
Gabriele Bergers,Douglas Hanahan +1 more
TL;DR: Emerging data support a proposition that two modes of unconventional resistance underlieAngiogenesis inhibitors targeting the vascular endothelial growth factor signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers.
MicroRNAs in cancer.
TL;DR: In this paper, the effects of miRNA dysregulation in the cellular pathways that lead to the progressive conversion of normal cells into cancer cells and the potential to develop new molecular miRNA-targeted therapies are discussed.
References
Inflammation and cancer
Lisa M. Coussens,Zena Werb +1 more
TL;DR: It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration.
14.4K
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
TL;DR: Emerging evidence supporting an alternative hypothesis is reviewed—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery.
5.4K
Angiogenesis in health and disease.
TL;DR: Molecular insights into the formation of new blood vessels are being generated at a rapidly increasing pace, offering new therapeutic opportunities that are currently being evaluated.
4.5K
Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion
Akira Orimo,Piyush Gupta,Dennis C. Sgroi,Fernando Arenzana-Seisdedos,Thierry Delaunay,Rizwan Naeem,Vincent J. Carey,Andrea L. Richardson,Robert A. Weinberg +8 more
TL;DR: Using a coimplantation tumor xenograft model, it is demonstrated that carcinoma-associated fibroblasts extracted from human breast carcinomas promote the growth of admixed breast carcinoma cells significantly more than do normal mammaries derived from the same patients.
3.5K
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Rosandra N. Kaplan,Rebecca D. Riba,Stergios Zacharoulis,Anna H. Bramley,Loic Vincent,Carla Costa,Daniel D. MacDonald,David K. Jin,Koji Shido,Scott A. Kerns,Zhenping Zhu,Daniel J. Hicklin,Yan Wu,Jeffrey L. Port,Nasser K. Altorki,Elisa Port,Davide Ruggero,Sergey V. Shmelkov,Kristian K. Jensen,Shahin Rafii,David Lyden +20 more
TL;DR: A requirement for VEGFR1+ haematopoietic progenitor cells that express vascular endothelial growth factor receptor 1 (VEGFR1) home to tumour-specific pre-metastatic sites and form cellular clusters before the arrival of tumour cells is demonstrated.